Introduction {#s1}
============

The Hedgehog (Hh) signaling pathway controls embryonic pattern formation and organogenesis, adult stem cells homeostasis and tissue maintenance, and is involved in the etiology of various tumors ([@bib7]). Ligand (Indian, Sonic, or Desert Hedgehog) engagement to receptor Smoothened (Smo) relieves the inhibition of Patched 1 (Ptch1) and upregulates Gli1/2 proteins, which increase the expression of proteins including Myc, Cyclin D, and Bcl2 and promote cell proliferation. Hedgehogs also activate the Rho/Rac pathway and increase the expression of Cyclin B in Smo-independent manners, which are regarded as the non-canonical pathway ([@bib7]). Human genetic studies have identified germline mutations in *Ptch1* as the cause of Gorlin syndrome, which is characterized by basal cell carcinoma, medulloblastoma, cartilage tumors, and ectopic ossification during adolescence and early adulthood ([@bib12]). Some of the patients also develop holoprosencephaly and autism ([@bib32]). Inhibitors for Smo or Gli1/2 are developed to treat the related tumors ([@bib3]).

IHH is mainly expressed in prehypertrophic chondrocytes and osteoblasts at puberty stages ([@bib23]). Genetic studies have shown that IHH signaling regulates proliferation and differentiation of osteoblasts and chondrocytes during skeletal development and repair ([@bib4]; [@bib24]; [@bib27]; [@bib33]; [@bib38]). IHH regulates chondrocyte proliferation and differentiation mainly via PTHrP ([@bib24]; [@bib41]), while IHH regulates osteoblast differentiation by controlling Runx2 expression via the canonical and non-canonical pathways ([@bib36]; [@bib45]). Interestingly, Wnt/β-Catenin signaling, a crucial regulator of skeletal development and remodeling, has been shown to mediate the effects of IHH signaling on osteoblast differentiation ([@bib9]; [@bib14]; [@bib17]; [@bib44]), but act upstream of and parallel to IHH signaling in chondrocyte survival and hypertrophy, respectively ([@bib28]). In addition, Hh signaling in mature osteoblasts upregulates RANKL expression and enhances osteoclastogenesis and bone resorption ([@bib29]). Thus, IHH signaling plays critical roles in skeletal development and remodeling.

Enchondromas and osteosarcomas are among the most common skeleton tumors and they are generally resistant to conventional chemo- and radio-therapies ([@bib2]; [@bib3]; [@bib20]; [@bib31]). There is an urgent need to identify druggable targets for treatment of these disorders, yet this is hampered by incomplete understanding of pathogenesis of these tumors and a lack of animal models that resemble the human disorders. Cartilage/bone tumors often show activated Hh signaling, resulted either from mutations in *EXT1/2*, *PTH1R*, or *SMO* or from elevated expression of hedgehog ligands or Gli proteins ([@bib5]; [@bib16]; [@bib34]; [@bib39]; [@bib40]). However, activation of Hh signaling, for example by deletion of *Ptch1* alone, in chondrocytes or osteoblasts does not cause tumorigenesis ([@bib8]; [@bib10]).

Here, we use *Prrx1-CreERT; Ptch1^f/f^* mice to study the functions of Hh signaling in mesenchymal stem/stromal cells (MSCs) during adolescence and show that activation of Hh signaling promotes MSC proliferation and osteogenic and chondrogenic differentiation but suppresses MSC adipogenic differentiation and leads to development of osteoarthritis-like phenotypes, enchondroma, and osteosarcoma. *Ptch1* deletion executes these functions via the canonical Hh pathway and activation of Wnt/β-Catenin pathway. This study thus sheds light on the origin of enchondroma and osteosarcoma and identifies Wnt/β-Catenin as a drug target for cartilage/bone tumor treatment.

Results {#s2}
=======

*Ptch1* deletion in Prrx1^+^ MSCs in young mice resulted in distorted joints and ectopic bone formation {#s2-1}
-------------------------------------------------------------------------------------------------------

To investigate the functions of Hh signaling in postnatal bone growth, we ablated *Ptch1* in Prrx1^+^ MSCs using inducible *Prrx1-CreERT* mice ([@bib21]), due to embryonic lethality of *Prrx1-Cre; Ptch1^f/f^* mice ([@bib8]). Prrx1 has been shown to mark osteoblasts and chondrocytes during development and growth and bone marrow (BM) cells marked by Prrx1 has been shown to have features of MSCs ([@bib30]). Four doses of tamoxifen (TAM) was intraperitoneally injected into P14 *Prrx1-CreERT; Ptch1^f/f^* mice, which were euthanized 2 months later, when the peak bone mass was obtained ([Figure 1A](#fig1){ref-type="fig"}). We found that *Ptch1* deletion led to a decrease in Patched 1 but an increase in Hh target gene *Gli1* in BM-MSCs ([Figure 1B](#fig1){ref-type="fig"}). *Prrx1-CreERT; Ptch1^f/f^* mice were significantly smaller and showed decreases in body weight and length compared with age- and gender-matched control mice ([Figure 1C--1E](#fig1){ref-type="fig"}). Similarly, femur and tibia lengths were decreased by 23.3% and 18.4%, respectively, in *Prrx1-CreERT; Ptch1^f/f^* mice ([Figure 1F](#fig1){ref-type="fig"}). X-ray and micro-CT imaging revealed that the mutant mice had deformed knee joints and rough bone surfaces, which are indicative of exostoses ([Figure 1G](#fig1){ref-type="fig"}). Joint deformation and exostoses were also observed in the phalanges of *Prrx1-CreERT; Ptch1^f/f^* mice, with the paws being swelled ([Figure 1H](#fig1){ref-type="fig"}). These results suggest that ablation of *Ptch1* in Prrx1^+^ MSCs disrupted bone and cartilage growth and led to joint deformation and ectopic bone growth.

![Ablation of *Ptch1* in young mice led to joint deformation and exostoses.\
(**A**) A schematic for the experimental design. (**B**) Western blot results showed that *Ptch1* was largely deleted in BM MSCs and this led to an increase in Gli1 protein. (**C**) *Prrx1-CreERT; Ptch1^f/f^* mice appeared smaller than control littermates 2 months after TAM injection. (**D**) *Prrx1-CreERT; Ptch1^f/f^* mice showed a decrease in body weight compared with control littermates,\*\*p\<0.01, n = 6. (**E**) *Prrx1-CreERT; Ptch1^f/f^* mice showed a decrease in body length compared with control littermates, \*p\<0.05, n = 6. (**F**) *Prrx1-CreERT; Ptch1^f/f^* mice showed a decrease in femur length compared with control littermates, \*p\<0.05, n = 6. (**G**) Radiographic and micro-CT images of hindlimb showed joint deformation and exostoses in *Prrx1-CreERT; Ptch1^f/f^* mice. (**H**) Radiographic and micro-CT images of the paws showed joint deformation and exostoses in *Prrx1-CreERT; Ptch1^f/f^* mice.](elife-50208-fig1){#fig1}

*Ptch1* deficiency in Prrx1^+^ MSCs led to osteoarthritis and enchondroma formation {#s2-2}
-----------------------------------------------------------------------------------

Histological analyses revealed that *Prrx1-CreERT; Ptch1^f/f^* mice exhibited signs of osteoarthritis with high OARSI scores at 2.5 months of age (2 months after TAM injection) ([Figure 2A and B](#fig2){ref-type="fig"}), and increased fibrotic cells lining the damaged cartilage surfaces, which were positive for fibrosis marker FSP1 ([Figure 2C and D](#fig2){ref-type="fig"}). The articular cartilage showed reduced Col2-expressing cells but increased Col10-expressing cells ([Figure 2E](#fig2){ref-type="fig"}). We isolated the articular cartilage from the mutant and control mice, carried out quantitative PCR analysis, and detected decreases in *Timp3* (encoding inhibitor of metalloproteinases-3), *Sox9, and Acan* but increases in *Mmp13* (encoding matrix degradation enzyme) and *Adamts5* in the mutant mice ([Figure 2F](#fig2){ref-type="fig"}). Compared to control littermates, the thickness of calcified cartilage (CC) layer was greater whereas the thickness of hyaline cartilage (HC) layer was lesser in the mutant mice ([Figure 2---figure supplement 1A and B](#fig2s1){ref-type="fig"}), accompanied by modest decreases in subchondral bone volume and bone mineral density (BMD) ([Figure 2---figure supplement 1C and D](#fig2s1){ref-type="fig"}). These results suggest that *Prrx1-CreERT; Ptch1^f/f^* mice developed phenotypes resembling early osteoarthritis, consistent with the finding that expression of Smo in Col2^+^ chondrocytes leads to development of osteoarthritis ([@bib26]).

![Ablation of *Ptch1* led to increased chondrocyte proliferation and development of osteoarthritis and enchondroma.\
(**A**) Safranin O staining of knee joints of *Prrx1-CreERT; Ptch1^f/f^* and control mice. (**B**) Increased OARSI scores of *Prrx1-CreERT; Ptch1^f/f^* mice compared to control littermates. \*\*p\<0.01 compared to the *Ptch1^f/f^* group, n = 9 per group. (**C**) Villanueva-Goldner\'s trichrome staining of articular cartilage of *Prrx1-CreERT; Ptch1^f/f^* and control mice. (**D**) Immunostaining for FSP1 of articular cartilage of *Prrx1-CreERT; Ptch1^f/f^* and control mice. (**E**) Immunostaining of Col2 (top) and Col10 (bottom) on the articular cartilage of femur bones in *Prrx1-CreERT; Ptch1^f/f^* and control mice. Right panel: quantitation data, \*p\<0.05, \*\*p\<0.01, n = 4. (**F**) Quantitative PCR analysis of articular cartilage samples of *Prrx1-CreERT; Ptch1^f/f^* and control mice revealed alteration of gene expression that indicated osteoarthritis phenotypes. All samples were normalized to GAPDH and then to the control samples, \*p\<0.05, \*\*p\<0.01, n = 3. (**G**) Safranin O staining showed multiple enchondroma-like lesions (EC) at growth plate, articular cartilage, and bone marrow in *Prrx1-CreERT; Ptch1^f/f^* mice. Higher magnification views of boxed areas were shown on the right. CB, cortical bone. (**H**) Ki67 immunohistochemistry at the growth plate of femurs of *Prrx1-CreERT; Ptch1^f/f^* and control mice. Right panel: Safranin O staining of section corresponding to tumor region. (**I**) Quantitation of Ki67^+^ cells at the growth plate of femur bones (non-tumor regions) of *Prrx1-CreERT; Ptch1^f/f^* and control mice, \*\*p\<0.01, n = 6. (**J**) Immunostaining of Col2 at the growth plate of femur in *Prrx1-CreERT; Ptch1^f/f^* and control mice. (**K**) Immunostaining of Col10 at the growth plate of femur in *Prrx1-CreERT; Ptch1^f/f^* and control mice.](elife-50208-fig2){#fig2}

Histological analyses of bone sections also revealed multiple enchondroma-like lesions (referred to as EC hereafter) at the growth plate, articular cartilage, and bone marrow (likely originated from the growth plate, see late results) in the mutant mice ([Figure 2G](#fig2){ref-type="fig"}). In addition, chondrocytes in the growth plate of mutant mice was improperly aligned, which also displayed an increase in Ki67 staining in the tumor region and the unaffected region ([Figure 2H and I](#fig2){ref-type="fig"}). Examination of mice at earlier time points post TAM administration detected EC-like overgrowth at both articular surfaces and growth plates at day 7, which became larger and invaded the trabecular areas over time ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). Expression of Col10 but not Col2 was increased at the growth plate ([Figure 2J and K](#fig2){ref-type="fig"}). Similar cartilage lesions were also observed in phalanges, humeri, and tibia but not in the vertebrae of mutant mice ([Figure 2---figure supplement 2B--2F](#fig2s2){ref-type="fig"}). Overall, *Ptch1* deletion in Prrx1^+^ MSCs promoted chondrocyte proliferation and enchondroma formation.

*Ptch1* deficiency led to osteosarcoma formation at periosteal surfaces {#s2-3}
-----------------------------------------------------------------------

*Prrx1-CreERT;Ptch1^f/f^* mice also developed tumors at the periosteal surfaces that have features of osteosarcoma: expansive osteoid lesions with mushroom-shaped appearance that were only located at cortical bones of the limbs ([Figure 3A--3D](#fig3){ref-type="fig"}), which later transgressed the cortex ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Note that exostoses, which were smaller and numerous, were observed in long bones and phalanges of *Prrx1-CreERT; Ptch1^f/f^* mice ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Osteosarcoma-like lesions (referred to as OS hereafter) also showed increased angiogenesis, with the blood vessels mainly located outside of the tumors ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). All (n = 9) *Prrx1-CreERT; Ptch1^f/f^* mice developed OS and they lived less than 7 months after TAM injection. Two of the mutant mice showed tumors in the lung ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), indicative of metastasis.

![*Prrx1-CreERT; Ptch1^f/f^* mice developed osteosarcoma.\
(**A**) H/E staining showed that osteoid lesions (arrows) were present in femur of *Prrx1-CreERT; Ptch1^f/f^* mice. OS, osteosarcoma; CB, cortical bone. (**B**) Representative presentation of osteosarcoma (OS) in forelimb (top) and hindlimb (bottom) in *Prrx1-CreERT; Ptch1^f/f^* mice 5 months after TAM injection. (**C**) Radiographic images of bone tumors in *Prrx1-CreERT; Ptch1^f/f^* mice 5 months after TAM injection. (**D**) Representative histological section of osteosarcoma in *Prrx1-CreERT; Ptch1^f/f^* mice 5 months after TAM injection. (**E**) Quantitative PCR analysis of Hh target genes of tumor tissues isolated from *Prrx1-CreERT; Ptch1^f/f^* mice. All samples were normalized to GAPDH and then to control periosteal cells (PC), \*p\<0.05, \*\*p\<0.01, n = 3. (**F**) Western blot showed an increase in Gli1 in bone tumor tissues isolated from *Prrx1-CreERT; Ptch1^f/f^* mice compared to normal periosteal cells. (**G**) Cell proliferation assays for primary osteosarcoma cells and control periosteal cells by Ki67 staining, Right panel: quantitation data. \*p\<0.05, n = 5. (**H**) Cell proliferation analysis of primary osteosarcoma cells and control periosteal cells using CKK8 assays, \*p\<0.05, n = 3. (**I**) Wound healing assay of primary osteosarcoma cells. Dotted lines indicated the cell fronts, Right panel: quantitation data. \*p\<0.05, \*\*p\<0.01, n = 4.](elife-50208-fig3){#fig3}

Quantitative PCR and western blot analyses confirmed that Hh signaling was activated in the OS tumors, manifested by increases in the expression of Gli1 protein and other IHH target genes compared to cultured periosteal cells ([Figure 3E and F](#fig3){ref-type="fig"}). We also isolated primary cells from osteosarcomas and cultured them for further analysis. Immunostaining results showed that there were more Ki67-poisitve cells in osteosarcoma cell cultures than normal periosteal cell cultures ([Figure 3G](#fig3){ref-type="fig"}). A significant increase in cell proliferation rate was also observed in osteosarcoma cells ([Figure 3H](#fig3){ref-type="fig"}). Wound healing assays revealed that osteosarcoma cells showed a significant increase in cell migration rate compared with periosteal cells ([Figure 3I](#fig3){ref-type="fig"}).

However, micro-CT analysis revealed no significant change in bone mass and the number or thickness of trabecular bones in *Prrx1-CreERT; Ptch1^f/f^* mice at 2.5 months of age ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). This could be due to the tight coupling between osteoblastogenesis and osteoclastogenesis caused by Hh activation ([@bib29]).

*Ptch1* deletion in Gli1^+^ chondrocytes/osteoprogenitors did not lead to tumor formation {#s2-4}
-----------------------------------------------------------------------------------------

The above results are in contrast to a previous study showing that *Col2α1-Cre-*mediated *Ptch1* deletion only led to delayed chondrocyte hypertrophy ([@bib28]). We also deleted *Ptch1* using *Gli1-CreERT* mouse, which was reported to label osteoprogenitors (underneath the growth plate) and chondrocytes ([@bib37]). We found that the mutant line did not develop tumors at all ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}), yet, they showed deceases in trabecular bones ([Figure 3---figure supplement 3B](#fig3s3){ref-type="fig"}). The lack of tumor formation in *Gli1-CreERT; Ptch1^f/f^* mice suggests that activation of Hh signaling in MSCs but not in chondrocytes or osteoprogenitors promotes tumorigenesis. Note that deletion of one allele of *Gli1*, like in *Gli1-CreERT* mice, does not affect *Ptch1* deficiency-induced tumorigenesis ([@bib22]).

*Ptch1* deletion produced skeletal phenotypes via the canonical Smo-Gli pathway {#s2-5}
-------------------------------------------------------------------------------

To test the contribution of canonical Hh signaling to *Ptch1* deficiency-induced skeletal defects and tumorigenesis, we treated *Prrx1-CreERT; Ptch1^f/f^* mice with Smo inhibitor cyclopamine or Gli1/2 inhibitor GANT61 for 2 months after TAM administration. X-ray and histological examination revealed that cyclopamine or GANT61 alleviated joint deformation and enchondroma formation, and restored the structures of articular cartilage and growth plate ([Figure 4A--4C](#fig4){ref-type="fig"}). Cyclopamine or GANT61 also diminished the development of osteosarcoma in *Prrx1-CreERT; Ptch1^f/f^* mice ([Figure 4D and E](#fig4){ref-type="fig"}). Overall, these findings indicate that Hh signaling regulates skeletal growth and promotes tumorigenesis via the Smo-Gli1/2 pathway.

![*Ptch1* deficiency induced cartilage/bone tumor formation via Smo-Gli1/2.\
(**A**) Radiographic images of *Prrx1-CreERT; Ptch1^f/f^* and control mice treated with cyclopamine or GANT61. (**B**) Safranin O staining showed that Cyclopamine or GANT61 rescued the disrupted articular cartilage and formation of enchondroma in *Prrx1-CreERT; Ptch1^f/f^* mice. (**C**) OARSI scores of control and *Prrx1-CreERT; Ptch1^f/f^* mice treated with either vehicle, Cyclopamine, or GANT61. \*\*p\<0.01 compared to the *Ptch1^f/f^* group; \# p\<0.05 compared to the vehicle-treated *Prrx1-CreERT; Ptch1^f/f^* group, n = 3 per group. (**D**) H/E staining showed that Cyclopamine or GANT61 rescued the osteosarcoma-like lesions in *Prrx1-CreERT; Ptch1^f/f^* mice. (**E**) Counts of osteogenic tumor-like nodules in control and *Prrx1-CreERT; Ptch1^f/f^* mice treated with either vehicle, Cyclopamine, or GANT61. \*\*p\<0.01 compared to the *Ptch1^f/f^* group; \# p\<0.05 compared to the vehicle-treated *Prrx1-CreERT; Ptch1^f/f^* group, n = 3 per group.](elife-50208-fig4){#fig4}

The origins of *Ptch1* deficiency-induced enchondroma and osteosarcoma {#s2-6}
----------------------------------------------------------------------

The above results indicate that deletion of *Ptch1* alone in Prrx1^+^ MSCs resulted in development of both enchondroma and osteosarcoma in the same mouse. To trace the origin of these tumors, we generated *Prrx1-CreERT;Ai14* and *Prrx1-CreERT; Ptch1^f/f^; Ai14* mice. Lineage tracing revealed that immediately after TAM injection, a few Ai14^+^ cells were detected in the articular cartilage, growth plate, periosteum, and large numbers of Ai14^+^ cells in the trabecular bones, whereas *Prrx1-CreERT; Ai14* mice without TAM administration showed no Ai14^+^ cells ([Figure 5A](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Over time, Ai14^+^ cells were expanded and replenished articular cartilage, growth plate, BM, and periosteum ([Figure 5A](#fig5){ref-type="fig"}), suggesting that Prrx1 may label stem/progenitor cells at these locations. *Ptch1* deletion led to further expansion of Prrx1 lineage cells ([Figure 5A](#fig5){ref-type="fig"}). Furthermore, Ai14^+^ enchondroma (at articular cartilage and growth plate) and OS-like lesions (at periosteal bone surfaces) were detected in *Prrx1-CreERT; Ptch1^f/f^; Ai14* mice at days 14 and 30 post TAM administration, respectively ([Figure 5A](#fig5){ref-type="fig"}), suggesting that *Ptch1* deletion quickly leads to overproliferation of MSCs or progenitors. More enchondromas and osteosarcomas were formed 2 months post TAM injection ([Figure 5B](#fig5){ref-type="fig"}). The growth plate did not show much differences in the thickness of different zones ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). These results suggest that the tumors are originated from Prrx1 lineage cells located at articular cartilage, growth plate, and periosteal bones but not at trabecular bones. On the other hand, Prrx1 marked limited numbers of osteoblasts and no chondrocytes in the vertebrae ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}), consistent with our observation that *Prrx1-CreERT; Ptch1^f/f^* mice did not develop tumors in vertebrae ([Figure 2---figure supplement 2E](#fig2s2){ref-type="fig"}).

![*Ptch1* deficiency-induced cartilage/bone tumors were originated from Prrx1 lineage cells.\
(**A**) Tracing results of 1, 14, and 30 days after 4 doses of TAM injection in *Prrx1-CreERT;Ptch1^f/f^; Ai14* and *Prrx1-CreERT; Ai14* mice. EC, enchondroma; OS, osteosarcoma. Upper panel: a schematic for the experimental design. (**B**) Lineage tracing of *Prrx1-CreERT; Ptch1^f/f^;Ai14* and *Prrx1-CreERT;Ai14* mice 2.5 months after TAM injection. Images showed that cells in the tumor region are Prrx1^+^ (red). White circles, enchondroma; yellow circles, osteosarcoma. EC, enchondroma; OS, osteosarcoma. (**C**) Immunostaining of chondrocyte and osteoblast markers on bone tumor sections. Left panel: H/E staining.](elife-50208-fig5){#fig5}

Evidence that enchondroma and osteosarcoma arise from chondrocyte and osteoblast progenitors, respectively {#s2-7}
----------------------------------------------------------------------------------------------------------

Previous studies have shown that Prrx1-marked BM cells have osteoblast, chondrocyte, and adipocyte differentiation potentials ([@bib30]). We found Prrx1-marked BM-MSCs accounted for more than 50% of the adherent MSCs ([Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}). Moreover, Prrx1^+^ cells isolated from periosteal surfaces of *Prrx1-CreERT;Ai14* mice (right after four daily doses of TAM) could form colony-forming units and had osteoblast, chondrocyte, and adipocyte differentiation potentials ([Figure 5---figure supplement 2B and C](#fig5s2){ref-type="fig"}). Prrx1^+^ cells could also differentiate into chondrocytes and osteoblasts during bone fracture repair in vivo (data not shown). Overall, these results suggest that Prrx1^+^ cells in bone marrow and periosteal bones are multipotent. Note that our tracing data indicate that enchondromas observed in BM cavities are originated from multipotent cells located in the growth plate but not BM MSCs.

Immunostaining revealed that Ai14^+^ enchondroma expressed low levels of Col2 and Col10, but not Col1 ([Figure 5C](#fig5){ref-type="fig"}), whereas Ai14^+^ osteosarcoma cells, which were located at periosteal surfaces, expressed low levels of Col1 but not Col2 or Col10 ([Figure 5C](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}), suggesting that these tumor cells were in a low-degree of differentiation state and that enchondroma and osteosarcoma arise from early chondrocyte and osteoblast progenitors, respectively. It is predicted that tumors derived from multipotent MSCs would contain both osteoblasts and chondrocytes, yet no such tumor was detected in *Prrx1-CreERT; Ptch1^f/f^* mice.

Hh signaling promotes Prrx1^+^ MSC proliferation and differentially regulates its tri-lineage differentiation {#s2-8}
-------------------------------------------------------------------------------------------------------------

We found that BM-MSCs from 2.5 month-old *Prrx1-CreERT; Ptch1^f/f^* mice showed an increase in colony forming units ([Figure 6A](#fig6){ref-type="fig"}), indicating that *Ptch1* ablation led to an expansion of the BM-MSC pool in vivo and/or increased cell proliferation. BM-MSCs isolated from *Prrx1-CreERT; Ptch1^f/f^; Ai14* mice indeed showed increased proliferation rates, manifested by an increase in Ki67-positive cells ([Figure 6B](#fig6){ref-type="fig"}), enhanced osteogenic and chondrogenic differentiation, manifested by increased histological staining ([Figure 6C](#fig6){ref-type="fig"}). We found that overexpression of *Ptch1* in BM-MSCs suppressed osteoblast and chondrocyte differentiation ([Figure 6---figure supplement 1A--1C](#fig6s1){ref-type="fig"}), demonstrating the negative roles for *Ptch1* in osteoblast and chondrocyte differentiation. *Ptch1*-deficient BM-MSCs also showed suppressed adipogenic differentiation, manifested by reduced levels of Oil Red O staining ([Figure 6C](#fig6){ref-type="fig"}), which is supported by the observation that *Prrx1-CreERT; Ptch1^f/f^* mice showed a decrease in Perilipin^+^ adipocytes in the bone marrow ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Analyses of expression of osteoblast, chondrocyte, and adipocyte markers confirmed these histological staining results ([Figure 6D](#fig6){ref-type="fig"}). We validated the effects of *Ptch1* ablation on MSC differentiation by transplantation assays. Carrier particles of hydroxyapatite tricalcium phosphate (HA/TCP) were mixed with MSCs and implanted subcutaneously under the dorsal skin of nude mice. After 8 weeks, the implants were harvested and analyzed. It was found that mutant MSCs formed more bone and fewer adipocytes in vivo than control MSCs ([Figure 6E](#fig6){ref-type="fig"}). We also used a cell pellet culture model to confirm the effects of *Ptch1* ablation on chondrogenic differentiation. MSCs isolated from mutant and control mice were pelleted by centrifugation and maintained in chondrogenic culture medium for 3 weeks. We found that the mutant MSCs showed increases in chondrocyte pellet size, which may be attributable to increased hypertrophic growth and increased proliferation, which were manifested by H/E, toluidine blue, and Ki67 staining ([Figure 6F and G](#fig6){ref-type="fig"}). Taken together, these results suggest that Hh signaling plays critical roles in MSC proliferation and differentiation.

![Critical roles for Hh signaling in MSC proliferation and differentiation.\
(**A**) Colony forming efficiency assay of BM MSCs isolated from *Prrx1-CreERT; Ptch1^f/f^* and control mice. These plates were stained with crystal violet. Right panels, quantitation data, \*p\<0.05, n = 3. (**B**) Cell proliferation of MSCs isolated from *Prrx1-CreERT; Ptch1^f/f^* and control mice by Ki67 staining. Right panel: quantitation data. \*p\<0.05, n = 3. (**C**) *Prrx1-CreERT; Ptch1^f/f^* MSCs showed an alteration in tri-lineage differentiation activities. Osteoblast differentiation was judged by Von Kossa and Alizarin Red staining, chondrocyte differentiation was judged by Toluidine Blue staining, and adipocyte differentiation was judged by Oil Red O staining. (**D**) Quantitative PCR analysis of lineage-specific markers of *Ptch1^-/-^* and control MSCs cultured with osteoblast medium, chondrocyte medium or adipocyte medium. All samples were normalized to GAPDH and then to the controls, \*p\<0.05, \*\*p\<0.01, n = 3. (**E**) H/E staining of histological sections from implanted *Ptch1^-/-^* and control MSC-scaffolds. Right panel, quantitative analysis of amount of bone and adipocytes that formed on the HA/TCP particles using Image-Pro Plus software based on H/E staining. HA/TCP, hydroxyapatite/tricalcium phosphate; B, bone; ad, adipocytes. Right panel: quantitation data. \*p\<0.05, n = 3. (**F**) Chondrocyte cells pellet images of differentiated *Ptch1^-/-^* and control BM MSCs. Right panel, quantitative data of pellet sizes. \*p\<0.05, n = 4. (**G**) Chondrocyte cell pellet assays of differentiation of *Ptch1^-/-^* and control BM MSCs. The same numbers of mutant and control MSCs were induced to differentiate into chondrocytes and the section were stained with H/E (left), toluidine blue (middle), or Ki67 (right).](elife-50208-fig6){#fig6}

*Ptch1* deficiency led to elevated expression of *Wnt5a* and *Wnt6* {#s2-9}
-------------------------------------------------------------------

We next searched for possible downstream mediators of *Ptch1* deficiency-induced tumorigenesis and other skeletal phenotypes. We compared activation of important signaling molecules that regulate chondrocyte and osteoblast proliferation and differentiation, in BM MSCs isolated from *Prrx1-CreERT; Ptch1^f/f^* and control mice by western blot. We found that *Ptch1* deficiency increased the activation of β-Catenin and Akt1 but suppressed the activation of Smad1/5/8 without affecting activation of Smad2/3 or Erk1/2 ([Figure 7A](#fig7){ref-type="fig"}). Immunostaining of bone sections also confirmed the changes in activation of these pathways ([Figure 7B](#fig7){ref-type="fig"}). *Ptch1* deficiency-induced increase in β-Catenin occurred in both the nucleus and cytoplasm ( Figure 7-figure supplement 1A). Furthermore, Hh signaling can activate β-Catenin in wildtype MSCs ([Figure 7---figure supplement 1B and C](#fig7s1){ref-type="fig"}). Previous studies have reported that Hh signaling interacts with BMP and WNT pathways to regulate cell fate determination ([@bib46]). However, suppressed Smad1/5/8 activation could not explain increased MSC differentiation into osteoblasts and chondrocytes. 

![Wnt/β-Catenin signaling was activated in *Ptch1^-/-^* MSCs and human bone/cartilage tumors.\
(**A**) Western blot results indicated that MSCs isolated from *Prrx1-CreERT; Ptch1^f/f^* mice showed enhanced activation of β-Catenin and Akt1 but decreased activation of Smad1/5/8. (**B**) Immunohistochemical staining confirmed that *Prrx1-CreERT; Ptch1^f/f^* mouse bone section showed increased β-Catenin and p-Akt1 signals but decreased p-Smad1/5/8 signals. Red circle, tumor region. (**C**) Quantitative PCR analysis of Wnt expression in MSCs isolated from *Prrx1-CreERT; Ptch1^f/f^* and control mice. All samples were normalized to GAPDH and then to the controls, \*\*p\<0.01, n = 3. (**D**) Sequence logos of 12-mer Gli1 binding motif was shown. (**E**) Schematic presentation of the putative Gli1-binding sites in the promoter region of mouse *Wnt5a* and *Wnt6.* (**F**) Quantitative PCR analysis of the immunoprecipitated DNA in separate experiments. \*\*p\<0.01 compared to the *Ptch1^f/f^* anti-Gli1 group. N = 4. (**G**) Representative images of Gli1 and β-Catenin expression in cartilage tumors by immunohistochemical staining. (**H**) Relationship between the protein levels of Gli1 and β-Catenin in human cartilage/bone tumors. Left: Bar graph presentation of co-expression between Gli1 and β-Catenin. Right: correlation analysis between Gli1 and β-Catenin, r = 0.8734, p\<0.0001.](elife-50208-fig7){#fig7}

Since the Wnt/β-Catenin pathway promotes proliferation and differentiation of both osteoblasts and chondrocytes, we determined the expression of 19 Wnt molecules in *Ptch1*^-/-^BM MSCs. Quantitative PCR analysis showed that *Wnt5a* and *Wnt6* were expressed at significantly higher levels in *Ptch1*^-/-^BM MSCs than control cells ([Figure 7C](#fig7){ref-type="fig"}). To test whether *Wnt5a* and *Wnt6* are target genes of Hh signaling, we performed chromatin-immunoprecipitation (ChIP) assays for Hh downstream transcription factor Gli1. We found that both *Wnt5a* and *Wnt6* contained two binding sites for Gli1 and moreover, binding of Gli1 to these sites were increased in *Ptch1* deficient cells ([Figure 7D--7F](#fig7){ref-type="fig"}). These results suggest that Hh signaling may activate transcription of *Wnt5a* and *Wnt6* in MSCs via Gli-1.

Human cartilage/bone tumor samples showed activation of both Hh and Wnt pathways {#s2-10}
--------------------------------------------------------------------------------

The above mouse studies established a link between Hh signaling and Wnt/β--Catenin signaling in skeletal growth and enchondroma/osteosarcoma development. Wnt/β--Catenin activation is a common event in various human tumors, especially in colorectal cancer ([@bib6]). We then tested whether Wnt/β--Catenin pathway was activated in human cartilage/bone tumors. Immunohistochemical staining of 24 human cartilage/bone tumors revealed that β--Catenin levels were increased in most of the tumor samples compared with normal tissues ([Figure 7G and H](#fig7){ref-type="fig"} and [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}), which was correlated with increased levels of Gli1 ([Figure 7H](#fig7){ref-type="fig"}). These results suggest that the link between Hh and Wnt/β--Catenin pathways also exists in human tumor samples.

Inhibition of Wnt/β-Catenin suppressed MSC proliferation and differentiation {#s2-11}
----------------------------------------------------------------------------

We then tested whether the Wnt/β-Catenin pathway mediated the effects of *Ptch1* deficiency on MSC proliferation and chondrogenic/osteogenic differentiation. To this end, we used IWP2 to inhibit Wnt/β-Catenin activation in MSC cultures. IWP2 is a small molecule compound that specifically inhibits Wnt signaling and has been used in many studies ([@bib11]; [@bib18]). We found that accelerated MSC proliferation caused by *Ptch1* ablation was markedly suppressed by IWP2 but not by BMP2 ([Figure 8A](#fig8){ref-type="fig"}). In addition, IWP2 blunted accelerated osteogenic and chondrogenic differentiation of *Ptch1*^-/-^MSCs while BMP2 enhanced the differentiation ([Figure 8B](#fig8){ref-type="fig"}). In addition, FH535, another Wnt/β-Catenin inhibitor, also suppressed accelerated osteogenic and chondrogenic differentiation of *Ptch1*^-/-^MSCs ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Overall, these results indicate that Wnt/β-Catenin mediates accelerated MSC proliferation and differentiation caused by *Ptch1* deletion.

![Wnt/β-Catenin mediated the pro-tumorigenic activity of *Ptch1* ablation.\
(**A**) IWP2 suppressed proliferation of BM-MSCs isolated from *Prrx1-CreERT; Ptch1^f/f^* mouse. Top, Ki67 staining; lower, cck8 assay. \*p\<0.05. (**B**) IWP2 rescued the enhanced osteogenic and chondrogenic differentiation of BM MSCs isolated from *Prrx1-CreERT; Ptch1^f/f^* mouse. (**C**) IWP2 inhibited Wnt/β-Catenin signaling without affecting the levels of Gli1. (**D**) Radiographic images showed that IWP2 rescued joint disruption and exostoses in *Prrx1-CreERT; Ptch1^f/f^* mouse. (**E**) Safranin O staining showed that IWP2 rescued joint disruption and cartilage tumor formation in *Prrx1-CreERT; Ptch1^f/f^* mouse. (**F**) OARSI scores of control and *Prrx1-CreERT; Ptch1^f/f^* mice treated with either vehicle or IWP2. \*\*p\<0.01 compared to the *Ptch1^f/f^* group; \# p\<0.05 compared to the vehicle-treated *Prrx1-CreERT; Ptch1^f/f^* group, n = 3 per group. (**G**) H/E-staining showed that IWP2 rescued bone tumor formation in *Prrx1-CreERT; Ptch1^f/f^* mouse. (**H**) Osteogenic tumor-like nodules counts in control and *Prrx1-CreERT; Ptch1^f/f^* mice treated with either vehicle or IWP2. \*\*p\<0.01 compared to the *Ptch1^f/f^* group; \#p\<0.05 compared to the vehicle-treated *Prrx1-CreERT; Ptch1^f/f^* group, n = 3 per group.](elife-50208-fig8){#fig8}

Inhibition of Wnt/β-Catenin suppressed tumor formation in *Prrx1-CreERT; Ptch1^f/f^* mice {#s2-12}
-----------------------------------------------------------------------------------------

Encouraged by the in vitro results on the effects of IWP2 on MSC proliferation and differentiation, we tested whether IWP2 could rescue the skeletal phonotypes observed in *Prrx1-CreERT; Ptch1^f/f^* mice. We treated *Prrx1-CreERT; Ptch1^f/f^* mice with IWP2 for 2 months right after TAM administration. IWP2 caused a decrease in the β--Catenin levels on bone sections without affecting the levels of Gli1 ([Figure 8C](#fig8){ref-type="fig"}). Importantly, IWP2 treatment rescued joint deformation and growth plate defects and diminished enchondroma and osteosarcoma formation of *Prrx1-CreERT; Ptch1^f/f^* mice ([Figure 8D--8H](#fig8){ref-type="fig"} and [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). Overall, these results suggest that enhanced Wnt/β--Catenin signaling is responsible for cartilage/bone growth defects and tumor development caused by *Ptch1* deficiency in MSCs.

Discussion {#s3}
==========

This study for the first time shows that deletion of *Ptch1* alone in Prrx1^+^ MSCs results in development of enchondromas and osteosarcomas in the same mice. This is in stark contrast to deletion of *Ptch1* in osteoblasts or chondrocytes and suggests that stemness or differentiation status of the cell plays a critical role in cartilage/bone tumorigenesis. We further show that *Ptch1*^-/-^enchondromas and osteosarcomas are derived from Prrx1^+^ lineage located at cartilage and periosteal bone, respectively and they express limited levels of markers for differentiated chondrocytes and osteoblasts, respectively. This is in line with the roles of Hh signaling in maintaining cancer stem cells. Although Prrx1^+^ MSCs located at different places including the periosteal bones have tri-lineage differentiation potentials, no tumor contains both chondrocytes and osteoblasts in *Prrx1-CreERT; Ptch1^f/f^* mice. These results, together with previous studies showing that multipotent stem cells must commit to unipotent progenitors in order for *Ptch1* deficiency to promote growth of medulloblastoma ([@bib35]; [@bib43]), suggest that enchondroma and osteosarcoma are originated from the early chondrocyte and osteoblast progenitors derived from the Prrx1^+^ MSCs. The underlying reason may be that progenitor cells have much greater proliferation activity than differentiated cells and multipotent stem cells.

The *Prrx1-CreERT; Ptch1^f/f^* mouse line is one of the few models for cartilage/bone tumors. Other models include mice with chondrocyte-specific Gli-2 overexpression and mice with chondrocyte-specific *Ext1* deletion ([@bib15]; [@bib16]). While Gli proteins can be activated by Erks, Akt1, and other pro-proliferating signals, Ext1/2 control synthesis of heparin sulphate and mutations of Ext genes may cause IHH diffusion and other effects ([@bib19]). In addition, deletion of *Ptch1* in osteoblasts using human osteocalcin-Cre in p53^+/-^but not p53^+/+^ background could induce osteosarcoma formation ([@bib10]). Here, we show that *Ptch1* deletion in Gli1-marked chondrocytes and osteoprogenitors does not cause tumorigenesis. Thus, *Prrx1-CreERT; Ptch1^f/f^* mouse represents a unique model useful for dissecting the initiation and progression of both enchondroma and osteosarcoma and for testing drug candidates to target these two tumors.

In addition, we show that Hh signaling promotes MSC proliferation and MSC osteogenic and chondrogenic differentiation but inhibits MSC adipogenic differentiation. While MSC-specific *Ptch1* deletion reproduces some of the phenotypes observed in chondrocyte- and/or osteoblast-specific *Ptch1* knockout mice, for example decreased body weight, body length and/or joint deformation, differences are also evident. *Prrx1-CreERT; Ptch1^f/f^* mice show unaltered bone mass, whereas *Ptch1* deletion in mature osteoblasts leads to a loss of bone mass due to increased bone resorption ([@bib29]). While deletion of *Ptch1* in Col2 chondrocytes results in a delay in hypertrophic growth ([@bib28]), we show that deletion of *Ptch1* in MSCs results in enhanced hypertrophic growth. In addition, *Ptch1* deletion in MSCs causes much severe joint deformation and exostoses and only *Ptch1* deletion in MSCs induces cartilage/bone tumor formation. These findings suggest that Hh activation-induced overproliferation and tumorigenesis occur in MSCs but not in differentiated daughter cells. We have previously reported that ectopic expression of HB-EGF or deletion of *Tsc1* (an mTOR inhibitor) in MSCs produces much severe cartilage and bone defects than similar genetic manipulation in chondrocytes and/or osteoblasts ([@bib25]). Taken together, these results indicate that in the process of osteoblast and chondrocyte production, important regulation may occur at stages of stem cell expansion and commitment.

It is known that Hh signaling promotes cell proliferation, inhibits apoptosis, and promotes tumorigenesis via the canonical and non-canonical pathways. Our current study clearly shows that the canonical pathway plays a critical role in *Ptch1* deficiency-induced enchondroma and osteosarcoma formation, as inhibitors for Smo or Gli1/2, which are developed as candidate drugs to treat cartilage and bone tumors ([@bib3]), suppressed tumorigenesis. In addition, we find that Wnt5a/6 are up-regulated in-*Ptch1* deficient MSCs and that β-Catenin is highly activated in mouse enchondroma and osteosarcoma samples. Previous studies have shown that canonical Wnt/β-Catenin signaling is essential for skeletal lineage differentiation ([@bib13]), and Wnt/β-Catenin signaling is also activated in most of the human cartilage/bone tumor samples, which is correlated with activation of Hh signaling. Functionally, inhibition of Wnt/β-Catenin signaling impedes development of cartilage/bone tumors and other skeletal growth defects. These findings underscore the roles played by the Wnt/β-Catenin pathway in Hh signaling-induced cell proliferation and tumorigenesis and suggest that inhibitors for Wnt/β-Catenin pathway may be useful for treating cartilage/bone tumors, especially the ones that are resistant to Hh signaling inhibitors.

Our findings thus uncover a functional link between Hh signaling and Wnt/β-Catenin signaling in MSC proliferation/differentiation, skeletal growth, and tumor formation. However, previous studies have revealed that in Col2^+^ chondrocytes, Wnt/β-Catenin may act upstream of or parallel to IHH pathway in controlling cell survival and joint development ([@bib28]). Although Hh pathway-driven development of basal cell carcinoma can be mediated by increased Wnt/β-Catenin signaling ([@bib42]), this is not a common theme as only a limited number of samples display this link ([@bib1]). Overall, these findings suggest that the functional link between Hh signaling and Wnt/β-Catenin may be specific to MSCs and progenitors of osteoblasts and chondrocytes. This is consistent with the pro-proliferation activity of Wnt/β-Catenin signaling in osteoblastogenesis and chondrogenesis.

In summary, our study has uncovered unanticipated functions of Hh signaling in MSCs, many of which are not observed in the daughter cells of MSCs. Hh activation promotes MSC proliferation and osteoblastic and chondrogenic differentiation but inhibits MSC adipogenic differentiation and leads to development of osteoarthritis, exostoses, and cartilage/bone tumors. Mechanistically, Hh signaling executes its pleiotropic effects via increasing the expression of a couple of Wnt molecules and enhancing Wnt/β-Catenin activation. Moreover, our genetic evidence suggests that enchondroma and osteosarcoma are derived from early progenitors of chondrocytes and osteoblasts and that Wnt/β-Catenin can be targeted to treat cartilage/bone tumors.

Materials and methods {#s4}
=====================

Mouse strains {#s4-1}
-------------

All mouse work was carried out following the recommendations from the National Research Council Guide for the Care and Use of Laboratory Animals, with the protocols approved by the Institutional Animal Care and Use Committee of Shanghai, China \[SYXK (SH) 2011--0112\]. ROSA-Ai14 (stock \#007914), *Gli1-CreERT* (stock \#007913), and Floxed *Ptch1* (stock \#030494) mouse lines were purchased from The Jackson Laboratory. These mice were kept in the SPF facility of Shanghai Jiao Tong University. *Ptch1^f/f^* mice were crossed with *Prrx1-CreERT* mice to generate *Prrx1-CreERT; Ptch1^f/f^* mice. *Prrx1-CreERT; Ptch1^f/f^* mice were crossed with ROSA-Ai14 mice to generate *Prrx1-CreERT; Ptch1^f/f^;Ai14* mice. *Ptch1^f/f^* mice were crossed with *Gli1-CreERT* mice to generate *Gli1-CreERT; Ptch1^f/f^* mice. In all mice, only one allele of *CreERT* is used.

X-ray and micro-CT analysis {#s4-2}
---------------------------

The whole-body and femur radiographs were taken using Cabinet X-Ray system (LX-60, Faxitron Bioptics) with standardized settings (45Kv for 8 s). Quantitative analysis was performed in mouse femur on a SkyScan-1176 micro-CT Scanner (Bruker micro-CT, Belgium), following the procedures provided by the manufacturer. Briefly, scanning was performed using 8.96 µm voxel size, 45KV, 500 µA and 0.6 degrees rotation step (180 degrees angular range) through the whole-length of the femora and extended proximally for 1400 slices. We started morphometric analysis with the first slice, where the femoral condyles were fully merged and extended for 150 slices proximally. Using a contouring tool, we segmented the trabecular bone from the cortical shell manually on key slices, and morphed the contours automatically to segment the trabecular bone on all slices. The three-dimensional structure and morphometry were constructed and analyzed for BV/TV (%), BMD (mg HA/mm^3^), Tb.N (mm^--1^), Tb.Th (mm) and Tb.Sp (mm).

Histological analysis {#s4-3}
---------------------

Femur and tibiae bones were fixed in 4% PBS-buffered paraformaldehyde overnight at 4°C. The samples were then stored in 70% alcohol for further experiments. For paraffin sections, samples were decalcified in 15% EDTA for 2 weeks and then dehydrated in alcohol, cleared with xylene, and embedded in paraffin. Four-μm-thick sections were cut using microtome (Lexica Microsystems Nussle GmbH). Hematoxylin and eosin (H/E) or Safranin O staining was carried out on bone sections. Stained slides were photographed under a light microscope (Olympus Microsystems).

OARSI measurement {#s4-4}
-----------------

Osteoarthritis severity was quantified by the Osteoarthritis Research Society International (OARSI) scoring system (0--6 for grade and 0--24 for score), which was assessed by a single observer who was blinded to the experimental groups. The average thickness of the articular cartilage of the femoral plateau was measured using Image-Pro Plus software.

Isolation and culture of BM-MSCs and periosteal cells {#s4-5}
-----------------------------------------------------

For BM MSC isolation, mice were euthanized and the femur and tibia were extracted and cleaned. The bone ends were cut off and the bone marrow was flushed out with α-MEM. Single cell suspension was filtered through a 70 μm mesh to remove the debris. BM MSCs were cultured in α-MEM containing 15% FBS, 100 μg/ml penicillin, and 100 μg/ml streptomycin, at 37°C for 5 days. The non-adherent cells were washed out and the BM MSCs were used for further experiments.

For periosteal cell isolation, mice were euthanized and the femur and tibia were extracted and cleaned. The whole bone was digested by dispase and type II collagenase at 37°C for 3 hr without flushing bone marrow out. The digested periosteal tissues were filtered through 70 μm cell strainers and then centrifuged. The cell pellet was resuspended in PBS for FACS sorting. The whole cells or sorted Ai14^+^ cells were cultured for further studies.

Colony-forming unit (CFU) assay {#s4-6}
-------------------------------

BM MSCs were plated at a density of 5 × 10^6^ cells per well in 12-well plates. After 7 days of culture with medium replaced every 3 days, the cultures were fixed and stained with crystal violet staining solution in methanol for 20 min. The dishes were washed with water and allowed to dry. Colonies were counted macroscopically, and data were reported as colony numbers per well.

Cell counting {#s4-7}
-------------

Cell proliferation was assessed using the Cell Counting Kit-8 (Sangon Biotech Co., Ltd., Shanghai, China). Brieﬂy, cells were seeded into duplicate wells of 96-well plates at a density of 1 × 10^3^ cells/well. At days 1, 2, 3, 4, and 5, 10 μl of cck-8 solution was added to each well. The samples were incubated for 4 hr at 37°C. The absorbance of each well was determined at 450 nm. Three independent experiments were performed.

Cell migration assay {#s4-8}
--------------------

Cells were pretreated with mitomycin C (4 mg/ml, Sigma-Aldrich) for 2 hr prior to analysis. Cell migration was monitored at 0, 10, 20 hr by introduction of a scratch in confluent cells.

Differentiation of MSCs {#s4-9}
-----------------------

To induce BM MSC tri-lineage differentiation, sorted Prrx1^+^ lineage BM MSCs were seeded at 5 × 10^4^/well in 12-well plates. The next day, the cells were switched into osteogenic medium with α-MEM medium containing 15% FBS, 10 mM β-glycerol phosphate, and 50 μg/ml ascorbic acid, for 7--10 days, with medium changed every 2 days. The cells were then fixed in 4% paraformaldehyde and stained for ALP using an Alkaline Phosphatase Kit (Sigma-Aldrich) or Alizarin red. For mineralization assay, the cells were cultured for 21 days, which were stained in 5% silver nitrate solution under ultraviolet light or 1% alizarin red S. The silver staining was terminated by adding sodium thiosulfate solution.

For adipocyte differentiation, BM MSCs were plated at 1 × 10^5^/well in a 12-well plate and cultured in α-MEM containing 15% FBS, 100 nM dexamethasone, and 5 μM insulin for 2 weeks. The cells were then fixed and stained with Oil red O solution.

For chondrogenesis assays, BM MSCs were suspended at a concentration of 1.6 × 10^7^ cells/ml. We generated micro-mass cultures by seeding 10 µl droplets of cell suspension at the center of 12-well plates. Cells were allowed to attach for 2 hr before adding α-MEM containing 15% FBS, 100 IU/ml penicillin, and 100 μg/ml streptomycin. After 1 day, the medium was replaced with chondrogenic medium in α-MEM containing 15% FBS, 100 nM dexamethasone, 10 ng/ml TGFβ1, and 1 μM ascorbate-2-phosphate. Cultures were maintained for 21 days, with the medium changed every 3 days, and were lastly stained with Alcian Blue or Toluidine blue.

In vivo ectopic bone formation assay {#s4-10}
------------------------------------

A total of 2 × 10^6^ isolated BM MSCs were collected and incubated with 40 mg hydroxyapatite/tricalcium phosphate carrier (HA/TCP: 12.5:87.5 by weight) (Bioengineering Research Center of Sichuan University, China) scaffolds for 6 hr at 37°C in humidifying incubator, and then implanted subcutaneously onto the back of 2-month-old BALB/C homozygous nude (nu/nu) mice (four mice per group). Mice were euthanized 10 weeks later after transplantation. The implants were fixed in 4% paraformaldehyde and then decalcified for 10 days. The sections were stained with H/E. To quantify the bone-like tissues, 10 images of each sample were taken randomly to measure the area of new bone formation versus total area.

Pellet culture assays (chondrogenesis) {#s4-11}
--------------------------------------

BM MSCs were suspended in chondrogenic medium consisting of high-glucose DMEM supplemented with 10 ng/ml recombinant human transforming growth factor-β3 (TGF-β3; R&D), 100 nM dexamethasone (Sigma), 50 μg L-ascorbic acid/ml (Sigma), 1 mM sodium pyruvate, 40 μg proline/ml and ITS + premix (Sigma; final concentrations: 6.25 μg/ml bovine insulin, 6.25 μg/ml transferrin, 6.25 μg/ml selenous acid, 5.33 μg/ml linoleic acid and 1.25 mg/ml bovine serum albumin). Aliquots of 5 × 10^5^ cells, suspended in 500 μl chondrogenic medium, were centrifuged at 300 g for 5 min in 15 ml polypropylene conical tubes. Pelleted cells were incubated at 37°C under 5% CO~2~ with loosened caps to permit gas exchange. Within 24 hr of incubation, the sedimented cells formed a spherical aggregate at the bottom of the tube. The medium was changed every 3 days and pellets were harvested after 6 weeks.

Quantitative PCR {#s4-12}
----------------

Total RNA was extracted using Trizol regent (Invitrogen), which was reverse transcribed using Transcriptor Universal cDNA Master (Roche) following the manufacturer's instructions. Quantitative PCR was carried out using Fast Start Universal SYBR Green Master kit (Roche) on ABI Prism 7500 Sequence Detection System (Applied Biosystems) using primers listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"} Table S1. The levels of different mRNA species were calculated with the delta-delta CT method and normalized to GAPDH. Significant difference was analyzed using two-tailed Student\'s t-test.

Immunofluorescence and immunohistochemical staining {#s4-13}
---------------------------------------------------

Decalcified bone sections were deparaffinized in xylene, rehydrated in ethanol, and permeabilized with 0.1% Triton X-100 for 20 min at room temperature. Antigen retrieval was performed in a citrate buffer at 95°C for 20 min. For immunostaining, the bone slides or cells on cover glass were blocked with 10% goat serum for 60 min, incubated with primary antibodies overnight at 4°C, washed in PBS, incubated with secondary antibody for 1 hr at 37°C, and washed with PBS before mounted on ProLong Gold DAPI (Life Technologies). The antibodies used in this study were: Col1α (ab21286, Abcam), Col2 (ab34712, Abcam), Col10 (ab58632, Abcam), CD31(550274, BD), Vimentin (ab92547, Abcam), Perilipin (ab3526, Abcam), Non-immune immunoglobulin G (IgG) (of the same species as the primary antibodies) used as negative control. The secondary antibodies were goat anti-rabbit Alexa Fluor 488 (ThermoFisher Scientific). Slides were mounted with antifade mounting medium with DAPI (ThermoFisher Scientific). Cell proliferation was determined by Ki67 immunofluorescence staining (Abcam, ab15580). Images were taken under Olympus DP72 microscope (Olympus Microsystems).

For immunohistochemical staining, endogenous peroxidase activity was quenched with 3% H~2~O~2~ in methanol for 20 mins followed by washing with PBS before primary antibody incubation. After incubation with secondary antibody, sections were developed with diaminobenzidine and counterstained with hematoxylin and then dehydrated and mounted in neutral resins. Primary antibodies were: Ki67 (ab15580, Abcam), p-Akt1 (4060S, CST), p-Smad1/5/8 (13820S, CST), FSP1 (ab27957, Abcam), Gli1(43926, SAB), β-Catenin (ab32572, Abcam), Non-immune immunoglobulin G (IgG) (of the same species as the primary antibodies) was used as negative controls.

Human bone tumor tissue arrays {#s4-14}
------------------------------

The human bone tumor tissue chips were provided by Alenabio (Xi'an, China). Each tissue chip was included 25 samples of human bone tumor with 10 chondrosarcoma, 8 osteosarcoma and 6 Ewing's sarcoma and one normal cartilage as control. The chips were stained with Gli1 ((43926, SAB) or β-Catenin ((ab32572, Abcam) antibodies under standard IHC protocol. The stained slides were examined under Olympus DP72 microscope (Olympus Microsystems), and images were acquired.

Western blot {#s4-15}
------------

Total proteins were extracted from cells or tissues with TNEN buffer containing phosphatase and proteinase inhibitors, quantitated by the Bradford method (Bio-Rad assay), and subjected to SDS-PAGE gel electrophoresis, which were transferred onto nitrocellulose membranes. The proteins were detected with specific antibodies using standard western blot method. The following antibodies were used: β-Actin (sc-47778, Santa Cruz), p-Akt1 (9271S, CST), Akt1 (9272S, CST), p-Erk1/2 (4377, CST), Erk1/2 (9102S, CST), p-Smad1/5/8 (9511L, CST), Smad1 (9743L, CST), Ptch1 (17520, Proteintech), Gli1 (2553S, CST), p-Smad2 (3101S, CST), p-Smad3 (9520S, CST), Smad2/3 (3102, CST), β-Catenin (ab32572, Abcam). Immunoreactivity was detected using a Western Chemiluminescent HRP Substrate Kit (Millipore) and imaged with FluorChem M system (Protein Simple).

SHH and inhibitor administration {#s4-16}
--------------------------------

For in vitro experiments, the IWP2 (Selleck Chemicals, USA) and FH535 (Selleck Chemicals, USA) were dissolved in dimethyl sulfoxide and applied at a final concentration of 10 μM and 20 μM in cell culture medium, respectively. Recombinant human sonic hedgehog (R and D systems, USA) was dissolved in PBS and applied at a final concentration of 5 μg/ml in cell culture medium.

For in vivo experiments, Cyclopamine (Selleck Chemicals, USA), GANT61 (Selleck Chemicals, USA), and IWP2 were reconstituted in corn oil. Mice were treated with 20 mg/kg cyclopamine, 30 mg/kg GANT61, or 10 mg/kg IWP2 through intragastric administration every other day after tamoxifen injection. Mice were treated for 2 months and then evaluated.

ChIP assay {#s4-17}
----------

The chromatin immunoprecipitation (ChIP) assay was carried out following the manufacturer's protocol (SimpleChIP Enzymatic Chromatin IP Kit, Agarose Beads, \#9002). Briefly, BMSCs were crosslinked with 1% formaldehyde and blocked with glycine, which were then washed and digested by micrococcal nuclease. The nuclear pellet was suspended in ChIP buffer and sheared by sonication. An aliquot of each sheared chromatin sample was set aside as input control. The remained chromatin was then incubated with anti-Gli1 antibody (Santa Cruz). Rabbit immunoglobulin G (IgG, \#9002, CST) was used as a control. The immunoprecipitated chromatins were then eluted with ChIP elution buffer. The DNA fragments were then released by treatment with ribonuclease A and then with proteinase K at 65°C. The released DNA fragments were purified with columns and amplified by site-specific primers by Real-time Quantitative PCR assay. The data were analyzed by the following formula: percent (%) input recovery = (100/(input fold dilution/bound fold dilution))×2(input CT−bound CT). Pairs of primers designed to amplify the specific target sequences of the putative promoters were listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"} Table S2.

Nuclear and cytoplasmic fractionation {#s4-18}
-------------------------------------

Cells were washed with ice-cold PBS and scraped from the wells with the plates on ice. A nuclear and cytoplasmic protein extraction kit (Beyotime, china) was applied to separate these two cellular components following the manufacturer\'s instructions. The immunoblotting procedure was performed as described before and the following antibodies were used: GAPDH (T40004S, abmart), H3 (ap50907, abgent), and β-Catenin (ab32572, Abcam) antibodies.

Virus production and infection {#s4-19}
------------------------------

To overexpress Ptch1 in BMSCs, PCR-amplified full-length human Ptch1 cDNA was tagged with Flag and subcloned into the pHBLV-CMV-Puro vector (Hanbio Biotechnology, China). Lentiviral vector carrying GFP was constructed as negative control. Recombinant viruses were collected and purified and titer was determined. For lentivirus infections, BMSCs were plated at a density of 1 × 10^5^ cells in 12 well-plate. LV-GFP, LV-hPtch1, or LV-Cre viruses were added at a multiplicity of infection of 20 when the cells were 30--50% confluent. After 72 hr, the transfected cells were harvested and gene overexpression was verified by Western blotting. For transient *Ptch1* deletion, primary *Ptch1^f/f^* MSCs were infected with Cre-expressing lentivirus.

Statistical analyses {#s4-20}
--------------------

Numerical data and histograms were expressed as the mean ± SD. Comparisons between two groups were analyzed using two-tailed unpaired Student's t test. p\<0.05 was considered statistically significant. Analysis of mice was litter-based and at least three litters were analyzed for every parameter. All the experiments were repeated at least three times.
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*Reviewer \#1:*

The authors show in this study that deletion of the inhibitor of the Indian Hedgehog (IHH) signaling pathway Patched 1 (Ptch1) in mesenchymal progenitor cells using *Prrx1-Cre* driver mice promotes osteoblast and chondrocyte differentiation and results in an osteoarthritis phenotype in 3 month old mice and appearance of tumors. The authors further try to link the appearance of these tumors to activation of the Wnt/β-Catenin pathway. This is potentially an important study and a red flag given the interest in Wnt signaling as a cure for otherwise milder diseases of the skeleton; however, this study needs to be fleshed out more to make a convincing argument.

\- The notion that Wnt signaling during development is need for chondrocyte differentiation is not known and was shown 15 years ago by one of the authors and by the Hartmann group, this should be acknowledged in a clearer manner.

\- The study of the mouse models is for now quite superficial: on what histological, molecular or phenotypic bases do the authors speak of osteosarcoma? When do these tumors appear? Do they metastasize as osteosarcoma do? How long do the mice live? This part of the study is sketchy and needs to expanded.

\- Can the authors link genetically IHH signaling and Wnt signaling in this cell type?

\- The authors show a clear increase in β-Catenin but they do not show whether it is cytoplasmic or nuclear.

*Reviewer \#2:*

This is a potentially interesting manuscript to provide a link between hedgehog (HH) and Wnt signaling in bone tumor biology. Both HH and Wnt signals have implicated in bone tumor formation such as osteosarcoma and enchondroma; thus their involvement is not novel. This manuscript suggests that by inactivation Ptch1 in postnatal (P14) bone marrow MSCs using the *Prrx1-CreERT* in mice, this would induce a constitutive activation of the Smo pathways in these cells, that subsequently contributes to a high incidence for the formation of osteosarcoma and enchondroma. They showed a correlation between activation of the HH pathway to Wnt, and propose that in this context of the MSCs, HH act upstream of Wnt. However, they further propose that osteosarcoma and enchondroma are formed from distinct progenitor lineages and not from a common multi-potential MSC pool. In support of their hypothesis, they provided evidence for the direct involvement of the HH pathway by inhibiting SMO and Gli2 in mice to suppress the formation of osteosarcoma and enchondroma, as with the inhibition of the Wnt pathway in mice.

While the data is interesting and supportive through association, more direct links are needed to support their claims. A major concern for me is the lack of a clear study of the initial pool of cells that were labeled in the cell tracing experiment, and thus the cells in which *Ptch1* are inactivated. They must show a thorough analysis of the cells in the axial and appendicular bones/cartilage and bone marrow immediately after the 4 days of TAM injection, and not 2.5 months later. Further, an elected time course study after TAM injection till 2.5 months would be informative and necessary as to the proliferative and differentiation of cells. It seem odd to me that the periosteal cells are labeled if Prrx1 only target MSCs. If it is indeed a more differentiated or committee pool of MSCs for the skeletal lineage, this would be interesting but need to be established.

The link between HH and Wnt is supportive, but not definitive. In development, the relationship between these two pathways is complex and context dependent. They propose that the function of HH in MSCs and chondrocytes, but this could just be the context that they are different cells, and therefore, the downstream outcomes are different.

Based on the concerns above, there is substantial correction and additional data required for further consideration.

In addition, while in general, the figures and data are of good quality, the presentation needs to be more stringent to provide the basic information for readers to follow and understand the key points. Generally, there is a lack of details in the description and labeling of the figures, with readers having to second guess what samples and what region(s) of the skeletal elements are being described. Figure 3---figure supplement 2 is missing.

*Reviewer \#3:*

The paper entitled \"Activation of Hedgehog signaling in mesenchymal stem cells induces cartilage and bone tumor formation via the Wnt/β-Catenin pathway\" is potentially interesting. The authors showed that *Ptch1* deletion led to development of osteoarthritis-like phenotypes, exostoses, enchondroma, and osteosarcoma in Smo-Gli1/2-dependent manners. *Ptch1* deletion increases the expression of *Wnt5a/6* and leads to enhanced β-Catenin activation. Inhibiting Wnt/β-Catenin pathway suppresses the development of skeletal anomalies, enchondroma, and osteosarcoma. The study is well designed and presented.

There are several issues:

How does *Ptch1* overexpression or knockdown affect osteoblasts and condroctytes?

Figure 1: It looks like that the bone density in *Ptch1* deletion is weaker?

Figure 2: It will be informative to measure cartilage thickness and subchondrol bone density as key OA parameters.

Figure 2: Have OARSI Osteoarthritis Cartilage Histopathology Assessment scores been measured?

Figure 3: When osteosarcoma was observed? And what percentage of mice? Will this lead to dead of the mice at later stage? Will overexpression of *Ptch1* rescue this phenotype?

Figure 4: Any quantitative measurement like OARSI scoring?

Figure 5E, F: Any quantitative measurement?

Figure 7E, F: Any quantitative measurement?

Figure 2---figure supplement 1: Any quantitative measurement?

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for submitting your article \"Activation of Hedgehog signaling in mesenchymal stem cells induces cartilage and bone tumor formation via Wnt/β-Catenin\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen Marianne Bronner as the Senior and Reviewing Editor. The following individual involved in review of your submission has agreed to reveal their identity: Danny Chan (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Essential Revisions:

The reviewers are mostly happy with your revision but ask you to make two essential changes:

1\) Improve their list of references, which is still self-referential and full of review articles instead of original articles.

2\) Resolve the issue in the cell tracing data from P14 as there was high autofluorescence, masking other potential location of *Prxx1* expressing cells. At the very least, it would be important to acknowledge the limitations in the Discussion.

Full reviews are attached below for further details.

Reviewer \#1:

The authors have addressed my questions and the manuscript has been improved.

Reviewer \#2:

This revision has largely addressed my concerns. The authors have provided additional data and clarified many of the issues. I only have a few comments for the authors to consider that I feel could further clarify the nature and source of the *Prrx1* expressing cells at P14 contributing to the formation of endochondroma and osteosarcoma.

Some concern still related to the data on the source of the \"MSCs\" labeled at P14 using the *Prxx1-Cre* mouse shown in Figure 5. While I appreciate the author\'s effort in addressing this critical issue, the autofluorescence signal makes it hard to delineate the precise location of cells that were labeled after the 4 consecutive injections with TAM. There is a need to show a control with vehicle injections to assess the level of autofluorescence. Further, the experiments for the differentiation of *Prxx1^+^* bone marrow MSCs and its correlation of the \"MSCs\" within the cartilage and periosteal bone is difficult to appreciate, as the context is very different. Can the author provide some assessment/comment on whether any of the marrow MSCs can contribute to the enchondromas as they have not eliminated such a possibility.

The overall finding is very interesting. In the Discussion, the authors have provide what we already know concerning the role of HH and Wnt signaling in skeletogenesis; can the authors comment on what could be the differences in the action of HH when it is activated in \"osteochondral progenitor cells\" as oppose to differentiated osteoblasts and chondrocytes with respective to the relationship between HH and Wnt signaling leading the formation of tumors.

Reviewer \#3:

The authors have addressed most of my experimental comments, which improves the paper. What remains and should be addressed for a high visibility paper is an extreme reliance on (1) review articles (for instance, 7 out of the first 16 references are review articles and it does not improve after) and (2) on citations of their own work or of their collaborators. This would be perfectly acceptable if they had done the original work but this is not the case. This needs to be addressed before going further.

10.7554/eLife.50208.028

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Reviewer \#1:
>
> The authors show in this study that deletion of the inhibitor of the Indian Hedgehog (IHH) signaling pathway patched 1 (Ptch1) in mesenchymal progenitor cells using Prrx1-Cre driver mice promotes osteoblast and chondrocyte differentiation and results in an osteoarthritis phenotype in 3 month old mice and appearance of tumors. The authors further try to link the appearance of these tumors to activation of the Wnt/β-Catenin pathway. This is potentially an important study and a red flag given the interest in Wnt signaling as a cure for otherwise milder diseases of the skeleton; however, this study needs to be fleshed out more to make a convincing argument.
>
> \- The notion that Wnt signaling during development is need for chondrocyte differentiation is not known and was shown 15 years ago by one of the authors and by the Hartmann group, this should be acknowledged in a clearer manner.

Thanks for pointing this out. We have cited these papers and described these findings in the new manuscript.

> \- The study of the mouse models is for now quite superficial: on what histological, molecular or phenotypic bases do the authors speak of osteosarcoma? When do these tumors appear? Do they metastasize as osteosarcoma do? How long do the mice live? This part of the study is sketchy and needs to expanded.

We agree with the reviewer. We have now added detailed description about osteosarcoma in the first paragraph of the subsection "Ptch1 deficiency led to osteosarcoma formation at periosteal surfaces".

In particular, the appearance and unique locations of the tumors, the histology of the tumors, the expression of osteoblast-specific but not chondrocyte-specific markers, and pulmonary metastasis (2 out of 9 mice) (new Figure 3---figure supplement 1D), support that these tumors are osteosarcoma. We also presented the time course analysis of enchondroma and osteosarcoma to show that these tumors developed early at day 14 for enchondroma and day 30 for osteosarcoma-like mass after induction of *Ptch1* deletion (new Figure 5A, Figure 2---figure supplement 2A, and Figure 3---figure supplement 1A). The mice can survive up to 7 months after TAM injection. We have included the information in the new manuscript.

> \- Can the authors link genetically IHH signaling and Wnt signaling in this cell type?

We have already shown that *Ptch1^-/-^* BM-MSCs displayed an increase in the β-Catenin protein and increases in mRNA levels of *Wnt5a* and *Wnt6* (Figure 7A and 7C). In addition, we treated MSCs with recombinant SHH and found that this led to activation of β-Catenin and increased expression of *Wnt5* and *Wnt6a*. However, SHH failed to further increase *Wnt5a* and *Wnt6* expression in *Ptch1^-/-^* BM-MSCs (new Figure 7---figure supplement 1B and 1C). Lastly, using *Ptch1^f/f^* BM-MSCs, we expressed Cre using viruses and found that transient deletion of Ptch1 led to activation of β-Catenin in the nucleus (new Figure 7---figure supplement 1A). These results established the link between IHH and Wnt signaling in BM-MSCs.

> \- The authors show a clear increase in β-Catenin but they do not show whether it is cytoplasmic or nuclear.

To address this point, we have fractionated the nuclear and cytoplasmic proteins from BM-MSCs and western blot results showed that there was an increase in both cytoplasmic and nuclear β-Catenin, supporting that the pathway was activated (new Figure 7---figure supplement 1A).

> Reviewer \#2:
>
> \[...\] While the data is interesting and supportive through association, more direct links are needed to support their claims. A major concern for me is the lack of a clear study of the initial pool of cells that were labeled in the cell tracing experiment, and thus the cells in which Ptch1 are inactivated. They must show a thorough analysis of the cells in the axial and appendicular bones/cartilage and bone marrow immediately after the 4 days of TAM injection, and not 2.5 months later. Further, an elected time course study after TAM injection till 2.5 months would be informative and necessary as to the proliferative and differentiation of cells. It seem odd to me that the periosteal cells are labeled if Prrx1 only target MSCs. If it is indeed a more differentiated or committee pool of MSCs for the skeletal lineage, this would be interesting but need to be established.

We traced the Prrx1 lineage cells at different time points after injecting Tamoxifen to 2 week-old *Prrx1-CreERT; tdTomato* mice. We found that Prrx1 could mark cells at the growth plate, endosteal bones, periosteal bones, and bone marrow in long bones (Figure 5A). However, it labelled much fewer osteoblasts and chondrocytes in the vertebrae (Figure 5---figure supplement 1B), suggesting that vertebral bones have different origins from long bones. This is consistent with our observation that deletion of *Ptch1* in *Prrx1^+^* cells did not affect vertebrae bone mass and cartilage or develop tumors (Figure 2---figure supplement 2). Moreover, the time course analysis showed that tumors developed early at day 14 for enchondroma and day 30 for osteosarcoma-like mass after induction of *Ptch1* deletion (Figure 5A, Figure 2---figure supplement 2A, and Figure 3---figure supplement 1A).

Recent studies have identified SSCs (MSCs) in the growth plate genetically marked by PthrP, periosteal SSCs marked by Cathepsin K, and perisinusoidal MSCs marked by Gremlin 1, Nestin, and LepR. SSCs isolated from these places have the potential to differentiate into osteoblasts, chondrocytes, and adipocytes. While previous studies have shown that Prrx1-marked BM-MSCs have tri-lineage differentiation potentials, we found that periosteal *Prrx1^+^* cells also have osteoblast, chondrocyte, and adipocyte differentiation potentials (Figure 5---figure supplement 2B-D). We further showed Prrx1-marked BM-MSCs account for more than 50% of adherent cells (Figure 5---figure supplement 2A). These results suggest that *Prrx1^+^* cells isolated from BM and periosteal bones are MSCs with multi-lineage potencies. Since deletion of *Ptch1* in mature osteoblasts and chondrocytes (including Gli1^+^ osteoprogenitors and chondrocytes) does not cause tumorigenesis (Figure 3---figure supplement 3), we conclude that it is the early progenitors that are transformed. Moreover, even after becoming tumor cells, they continue to progress into the specific lineage. We conclude that Prrx1 may mark cells at several places in the skeleton that have tri-lineage differentiation potentials.

> The link between HH and Wnt is supportive, but not definitive. In development, the relationship between these two pathways is complex and context dependent. They propose that the function of HH in MSCs and chondrocytes, but this could just be the context that they are different cells, and therefore, the downstream outcomes are different.

We agree that the crosstalk between HH and Wnt pathways can be affected by contexts. However, our ChIP experiments revealed that the promoters of Wnt5a and Wnt6 contain 2 bonding sites for Gli1, suggesting a direct link (Figure 7D-F). Since the promoters usually have binding sites for other transcription factors, the HH-Gli1-Wnt pathway can still be affected by cell context.

> Based on the concerns above, there is substantial correction and additional data required for further consideration.

We have done required experiments and included the new results in the new manuscript.

> In addition, while in general, the figures and data are of good quality, the presentation needs to be more stringent to provide the basic information for readers to follow and understand the key points. Generally, there is a lack of details in the description and labeling of the figures, with readers having to second guess what samples and what region(s) of the skeletal elements are being described. Figure 3---figure supplement 2 is missing.

We have added more labeling and arrows in the figures, expanded the legend, and also put back the missing figure.

> Reviewer \#3:
>
> The paper entitled \"Activation of Hedgehog signaling in mesenchymal stem cells induces cartilage and bone tumor formation via the Wnt/β-Catenin pathway\" is potentially interesting. The authors showed that Ptch1 deletion led to development of osteoarthritis-like phenotypes, exostoses, enchondroma, and osteosarcoma in Smo-Gli1/2-dependent manners. Ptch1 deletion increases the expression of Wnt5a/6 and leads to enhanced β-Catenin activation. Inhibiting Wnt/β-Catenin pathway suppresses the development of skeletal anomalies, enchondroma, and osteosarcoma. The study is well designed and presented.
>
> There are several issues:
>
> How does Ptch1 overexpression or knockdown affect osteoblasts and condroctytes?

We overexpressed *Ptch1* in wildtype MSCs by virus and found that this inhibited osteoblast and chondrocyte differentiation (new Figure 6---figure supplement 1).

Many of the BM-MSC differentiation data were done using *Ptch1^f/f^* MSCs, which were infected with Cre-expressing viruses, leading to partial deletion of Ptch1. We found that transient deletion of Ptch1 produced similar results as BM-MSCs isolated from *Prrx1-CreERT;Ptch1^f/f^* mice (TAM injected). These transient deletion cells should be similar to knock-down cells. We describe this in the new submission (new Figure 7---figure supplement 1A).

> Figure 1: It looks like that the bone density in Ptch1 deletion is weaker?

We performed micro-CT analysis in 4 pairs of mice and found that the bone density showed no significant change in *Ptch1* deletion mice (Figure 3---figure supplement 2). We have now used a more representative image.

> Figure 2: It will be informative to measure cartilage thickness and subchondrol bone density as key OA parameters.

We have measured the cartilage thickness by Image pro Plus software based on H/E staining images and subchondral bone density by micro-CT. The results are presented in new Figure 2---figure supplement 1B-D, and described in the new manuscript.

> Figure 2: Have OARSI Osteoarthritis Cartilage Histopathology Assessment scores been measured?

We have measured the Osteoarthritis Cartilage Histopathology Assessment scores according to Safranin O staining based on OARSI system (0--6 for grade and 0--24 for score). The results are presented in new Figure 2B and described in the new manuscript, which are indicative of early OA.

> Figure 3: When osteosarcoma was observed? And what percentage of mice? Will this lead to dead of the mice at later stage? Will overexpression of Ptch1 rescue this phenotype?

The tumor-like mass was observed in *Prrx1-CreERT;Ptch1^f/f^* 30 days after TAM injection. All 9 mice developed megascopic osteosarcoma. These mice can survive up to 7 months after TAM injection. We have added the description in new manuscript.

Generation of Ptch1 overexpression mice will take a long time. In addition, overexpression of Ptch1, similar to deletion of Smoothened, may cause embryo survival defects. Nevertheless, we used 2 inhibitors of Hh signaling and found these phenotypes are rescued. This should be sufficient to prove the point.

> Figure 4: Any quantitative measurement like OARSI scoring?

We have added the OARSI scores in new Figure 4C.

> Figure 5E, F: Any quantitative measurement?

We have added quantitative measurement of bone formation rate, adipocytes ratio and chondrogenic pellet sizes, respectively in new Figure 6E and 6F.

> Figure 7E, F: Any quantitative measurement?

We have added quantitative data on the numbers of osteogenic tumor-like nodules and OARSI scores in new Figure 8F and 8H.

> Figure 2---figure supplement 1: Any quantitative measurement?

We have added statistical results of tumor counts in new Figure 2---figure supplement 2F.

\[Editors\' note: the author responses to the re-review follow.\]

> Essential Revisions:
>
> The reviewers are mostly happy with your revision but ask you to make two essential changes:
>
> 1\) Improve their list of references, which is still self-referential and full of review articles instead of original articles.

We have removed 3 references authored by us and 13 other review article references.

> 2\) Resolve the issue in the cell tracing data from P14 as there was high autofluorescence, masking other potential location of Prxx1 expressing cells. At the very least, it would be important to acknowledge the limitations in the Discussion.

We have included a control image to show that autofluorescence is low (Figure 5---figure supplement 1A).

> Full reviews are attached below for further details.
>
> Reviewer \#2:
>
> This revision has largely addressed my concerns. The authors have provided additional data and clarified many of the issues. I only have a few comments for the authors to consider that I feel could further clarify the nature and source of the Prrx1 expressing cells at P14 contributing to the formation of endochondroma and osteosarcoma.

We have included a control image to show that autofluorescence is low (Figure 5---figure supplement 1A).

> Some concern still related to the data on the source of the \"MSCs\" labeled at P14 using the Prxx1-Cre mouse shown in Figure 5. While I appreciate the author\'s effort in addressing this critical issue, the autofluorescence signal makes it hard to delineate the precise location of cells that were labeled after the 4 consecutive injections with TAM. There is a need to show a control with vehicle injections to assess the level of autofluorescence. Further, the experiments for the differentiation of Prxx1^+^ bone marrow MSCs and its correlation of the \"MSCs\" within the cartilage and periosteal bone is difficult to appreciate, as the context is very different. Can the author provide some assessment/comment on whether any of the marrow MSCs can contribute to the enchondromas as they have not eliminated such a possibility.

We commented on this in the revised manuscript.

> The overall finding is very interesting. In the Discussion, the authors have provide what we already know concerning the role of HH and Wnt signaling in skeletogenesis; can the authors comment on what could be the differences in the action of HH when it is activated in \"osteochondral progenitor cells\" as oppose to differentiated osteoblasts and chondrocytes with respective to the relationship between HH and Wnt signaling leading the formation of tumors.

We commented on this in the revised manuscript (Discussion section).

> Reviewer \#3:
>
> The authors have addressed most of my experimental comments, which improves the paper. What remains and should be addressed for a high visibility paper is an extreme reliance on (1) review articles (for instance, 7 out of the first 16 references are review articles and it does not improve after) and (2) on citations of their own work or of their collaborators. This would be perfectly acceptable if they had done the original work but this is not the case. This needs to be addressed before going further.

We have removed 3 references authored by us and 13 other review-article references.

[^1]: These authors contributed equally to this work.
